Food, Drugs, Healthcare, Life Sciences

The life science real estate market is undergoing a period of adjustment in 2025, marked by ups and downs in different segments of the life science sector.

On July 31, 2025, the U.S. Department of Justice (DOJ) announced its first-ever (to our knowledge) cyber FCA settlement involving a medical device company.

The Department of Health and Human Services Office of Inspector General (OIG) has longstanding concerns about physician-owned entities that earn revenue...

On August 20, 2025, a federal judge in the Eastern District of Pennsylvania ruled that Caremark should pay nearly $290 million in damages and penalties for overbilling the government for Medicare Part D drugs.

U.S. Food and Drug Administration (FDA) food standards are experiencing the most activity in a generation, with FDA aiming to revoke 52 food standards followed by a proposal to revise the orange juice standard.

In March 2020, Congress enacted the first Over-the-Counter (OTC) Monograph Drug User Fee program (OMUFA) as part of the CARES Act (P.L. 116 – 136) to modernize the Food and Drug Administration's regulation of OTC monograph drugs, including authorizing the agency to carry out a user fee program in furtherance of this work.

For nurses and other healthcare providers, being ordered to appear for a deposition in a pressure injury case can be daunting. You may naturally worry that opposing counsel will expect you to recall...

On August 20, 2025, a federal judge in the Eastern District of Pennsylvania ruled that Caremark should pay nearly $290 million in damages and penalties for overbilling the government for Medicare Part D drugs.

In hospitals, clinics, and care facilities, healthcare professionals work tirelessly to support others, often under intense pressure.

In Otsuka Pharmaceutical Co. v. Sandoz, Inc., the Federal Circuit upheld the district court’s determination that the claims at issue were neither obvious nor invalid under the doctrine of obviousness-type double patenting based on a "lead compound" approach to the obviousness determinations.

After the Supreme Court decided that the personalized medicine method claims at issue in Mayo Collaborative Services v. Prometheus Laboratories, Inc. did not satisfy the patent eligibility requirements of 35 USC § 101.

GlaxoSmithKline and Genentech have settled a U.S. lawsuit related to Genentech's Cabilly II (US 6,331,415) and Cabilly III (US 7,923,221) patents.